#THRD

StockTitan

@stocktitan.net

9 months ago

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335 Third Harmonic Bio (THRD) announced stockholder approval of its Plan of Liquidation and Dissolution with 99.9% of voting shares in favor. The company expects to make an initial distribution of $5.30-$5.35 per share in Q3 2025, with total distributions estimated between $5.30-$5.44 per share. Additionally, THRD reported positive Phase 1 clinical data for THB335, their oral wild-type KIT inhibitor, showing 85% serum tryptase reduction at 100mg daily dose with an encouraging safety profile. The company has completed all requirements for Phase 2 trials in chronic spontaneous urticaria and plans to submit FDA filing. As part of the dissolution plan, THRD is initiating a sale process for THB335 and related intellectual property.

#THRD Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

www.stocktitan.net/news/THRD/third-harmonic...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks overbought with declining relative strength, Wed Jun 11th - #NEGG #LIMN #KYTX #FTEK #EYEN #CMPX #BIRD #AKBA #YEXT #SANA #THRD #ULBI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

Third Harmonic's $285M War Chest Powers Phase 2 CSU Drug Development Amid Strategic Shift Phase 1 success propels THB335 to Phase 2 trials, backed by $285M cash reserve. Strategic alternatives process launched to maximize value. See full analysis.

#THRD Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/THRD/third-harmonic...

Gilbert Gerber

@giger1964.bsky.social

1 year ago

Clearly cKIt (CD117) is not the right target to go after in CSU ! After Celldex #CLDX mAb in 09/24, Jasper #JSPR mAb in 01/25, today it's Third Harmonic #THRD small molecule to take the plunge. Enanta #ENTA SME is still preclinical. Inflarx #IFRX anti C5aR looks all the more promissing (Precli+ph1)

StockTitan

@stocktitan.net

1 year ago

Third Harmonic's CSU Drug Shows 84% Disease Marker Reduction, Company Eyes Strategic Options THB335 achieves significant tryptase reductions in Phase 1, advances to Phase 2 for chronic urticaria. Company initiates strategic review with $285M cash position.

#THRD Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

www.stocktitan.net/news/THRD/third-harmonic...

StockTitan

@stocktitan.net

1 year ago

#THRD Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/THRD/third-harmonic...